Valsts: Singapūra
Valoda: angļu
Klimata pārmaiņas: HSA (Health Sciences Authority)
Clarithromycin
ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED
J01FA09
500 mg
TABLET, FILM COATED
Clarithromycin 500 mg
ORAL
Prescription Only
Aesica Queenborough Limited
ACTIVE
1997-02-13
KLACID ® / KLACID ® FORTE 1. NAME OF THE MEDICINAL PRODUCT Clarithromycin 250mg, Immediate-Release Tablets Clarithromycin 500mg, Immediate-Release Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clarithromycin 250mg, Immediate-Release Tablet: One tablet contains 250mg Clarithromycin Tablet sodium content: 3.4 mg tablet Clarithromycin 500mg, Immediate-Release Tablet: One tablet contains 500mg Clarithromycin Tablet sodium content: 6.1 mg tablet For the full list of excipients, see PHARMACEUTICAL PARTICULARS, LIST OF EXCIPIENTS. 3. PHARMACEUTICAL FORM FORMULATION PHARMACEUTICAL FORM Clarithromycin IR Tablets Yellow, ovaloid film-coated tablet 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Klacid is indicated for treatment of infections caused by one or more susceptible organisms. Indications include: Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia. Upper respiratory tract infections for example, sinusitus and pharyngitis. Klacid is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active _in vitro _against common and atypical respiratory pathogens as listed in the microbiology section. Klacid is also indicated in skin and soft tissue infections of mild to moderate severity. Klacid in the presence of acid suppression effected by omeprazole is also indicated for the eradication of _H. pylori _ in patients with proven duodenal ulcers. See Dosage and Administration section. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION DOSAGE AND ADMINISTRATION RESPIRATORY TRACT/SKIN AND SOFT TISSUE INFECTIONS ADULTS: The usual dose in adults and children 12 years of age or older, is 250 mg twice daily for 7 days although this may be increased t Izlasiet visu dokumentu
KLACID ® / KLACID ® FORTE 1. NAME OF THE MEDICINAL PRODUCT Clarithromycin 250mg, Immediate-Release Tablets (IR) Clarithromycin 500mg, Immediate-Release Tablets (IR) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clarithromycin 250mg, Immediate-Release Tablet: One tablet contains 250mg Clarithromycin Tablet sodium content: 3.4 mg tablet Clarithromycin 500mg, Immediate-Release Tablet: One tablet contains 500mg Clarithromycin Tablet sodium content: 6.1 mg tablet For the full list of excipients, see PHARMACEUTICAL PARTICULARS, List of excipients. 3. PHARMACEUTICAL FORM Formulation Pharmaceutical Form Clarithromycin IR Tablets Yellow, ovaloid film-coated tablet 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Klacid ® is indicated for treatment of infections caused by one or more susceptible organisms in adults and children 12 years and older. Indications include: 1. Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing). 2. Upper respiratory tract infections for example, sinusitis and pharyngitis. 3. Klacid ® is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. 4. Klacid ® is also indicated in skin and soft tissue infections of mild to moderate severity (see section 4.4 and 5.1 regarding Sensitivity Testing). 5. Klacid ® in the presence of acid suppression effected by omeprazole is also indicated for the eradication of H. pylori in patients with proven duodenal ulcers. See Dosage and Administration section. Consideration should be given to national official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Dosage and Administration Respiratory tract/skin and soft tissue infections Adults: The usual dose in adults and children 12 years of age or older, is 250 mg twice daily for 7 days although this may be increased to Izlasiet visu dokumentu